Regenerated Cellulose-Based Hemodialyzers with Immobilized Proteins as Potential Devices for Extracorporeal Immunoadsorption Procedures: An Assessment of Protein Coupling Capacity and In Vitro Dialysis Performances

Artificial Organs

Volumn 20, Issue 1, 1996, Pages 8-16

  Vallar, Laurent ^a   Rivat, Claude ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

Activation; Extracorporeal immunoadsorption; In vitro clearance; In vitro ultrafiltration; Protein immobilization; Regenerated cellulose (Cuprophan) based hemodialyzer

Indexed keywords

BLOOD; CELLULOSE; CONTRAST MEDIA; PROTEINS; ULTRAFILTRATION;

CUPROPHAN; EXTRACORPOREAL IMMUNOADSORPTION; IMMUNOADSORPTION; IN VITRO CLEARANCE; IN VITRO ULTRAFILTRATION; IN-VITRO; PROTEIN IMMOBILIZATION; REGENERATED CELLULOSE; REGENERATED CELLULOSE (CUPROPHAN)-BASED HEMODIALYZER;

CHEMICAL ACTIVATION;

BOVINAE;

CELLULOSE;

ARTICLE; CLEARANCE; EXTRACORPOREAL CIRCULATION; HEMODIALYSIS; IMMUNOADSORPTION; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION; ULTRAFILTRATION;

EID: 0030049513     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1996.tb04412.x     Document Type: Article

References (32)

1. Bensinger WI, Baker DA, Buckner CD, Clift RA, Thomas ED. Immunoadsorption for removal of A and B blood group antibodies. New Engl J Med 1980;304:160-6.
2. Regnault V, Rivat C, Vallet JP, Francois-Gerard C, Bronchier G, Allain JP. A potential new procedure for removing anti-factor VIII antibodies from hemophilic plasma. Thromb Res 1987;45:51-7.
3. Bratt T, Ohlson S. The development of a C1q anti-C1q immunoadsorbent for removal of immune complexes from plasma. J Clin Lab Immunol 1988;27:191-5.
4. Gorchakov VD, Sakodynskii KI, Lebedin YS, Chuchalin AG. Immunoadsorbents for clinical use: ex vivo immunoglobulin E removal in allergy. J Chromatogr 1991;563: 166-71.
5. El Habib R, Coulet PR, Sanhadji K, Gautheron DC, Laville M, Traeger J. DNA immobilized onto an acyl-azide derivative of collagen membranes for use as immunoadsorbent. Biotechnol Bioeng 1984;26:665-9.
6. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoproteins in familial hypercholesterolemia. Lancet 1981;11:1005-7.
7. Regnault V, Costa PMP, Teixeira A, Rivat C, Stoltz JF, Saraiva MJM, Costa PP. Specific removal of transthyretin from plasma of patients with familial amyloidotic polyneuropathy: optimization of an immunoadsorption procedure. Int J Artif Organs 1992;15:249-55.
8. 2-microglobulin. Biochem Biophys Res Commun 1985; 129:701-6.
9. Gorevic PD, Casey TT, Stone WJ, Diramondo CR, Prelli FC, Frangione B. Beta-2-microglobulin is an amyloidogenic protein in man. J Clin Invest 1985;76:2425-9.
10. Gejyo F, Homma N, Arakawa M. Long-term complications of dialysis: pathogenic factors with special reference to amyloidosis. Kidney Int 1993;43:S78-82.
11. Brancaccio D, Gallieni M, Anelli A, Padovese P, Sabbioni E, Berlin A. Generation and removal of beta-2-microglobulin by dialysis. In: Gejyo F, Brancaccio D, Bardin T, eds. Dialysis amyloidosis. Milano: Wichtig Editore srl, 1989: 131-40.
12. 2-microglobulin removal by different hemodialysis membranes: a six-year follow-up. Nephron 1993;63:368-9.
13. 2-microglobulin. In: Isobe T, Araki S, Uchino F, Kito S, Tsubura E, eds. Amyloid and amyloidosis. New York: Plenum Publishers, 1988:629-34.
14. Vallar L, Costa PMP, Teixeira A, Pfister M, Barrois R, Costa PP, Rivat C. Immunoadsorption procedure as a potential method for the specific beta-2-microglobulin removal from plasma of patients with chronic renal failure. J Chromatogr B 1995;664:97-106.
15. Jackson JA, Halvorson HR, Furlong JW, Lucast KD, Shore JD. A new extracorporeal reactor-dialyzer for enzyme therapy using immobilized L-asparaginase. J Pharmacol Exp Ther 1979;209:271-4.
16. Kohn J, Wilchek M. A colorimetric method for monitoring activation of Sepharose by cyanogen bromide. Biochem Biophys Res Commun 1978;84:7-14.
17. Dumler F, Singh P, Jackson CE, Kini KR, Samhouri AM, Halvorson HR, Shore JD. Extracorporeal enzyme therapy: use of an L-asparaginase reactor-dialyzer in chemical setting. ASAIO 1981;4:70-7.
18. Larue C, Munnich A, Charpentier C, Saudubray JM, Frezal J, Remy MH, Rivat C. An extracorporeal hollow fiber reactor for phenylketonuria using immobilized phenylalanine ammonia lyase. Dev Pharmacol Ther 1986;9:73-81.
19. Singh P, Goldman J, Jackson CE. Preparation and in-vitro evaluation of a new extra-corporeal dialyzer with immobilized insulin. Artif Organs 1982;6:145-52.
20. Larue C, Gueraud V, Rivat C. Suitable hollow fibre immunobioreactors for specific ex vivo removal of antibodies and antigens from plasma. Clin Exp Immunol 1985;62:217-24.
21. Gadd KF. Cellulose films: a student project 1. The Cuprammonium process. Ed Chem 1984;21:15-7.
22. Klein E, ed. Affinity membranes. New York: John Wiley & Sons, Inc., 1991.
23. Filho GR, Bueno WA. Water state of Cuprophan (hemodialysis membrane). J Membrane Sci 1992;74:19-27.
24. Bensinger WI, Baker DA, Buckner CD, Clift RA, Thomas ED. Immunoadsorption for removal of A and B blood-group antibodies. New Engl J Med 1981;304:160-2.
25. De Vito LD, Sollinger HW, Burlingham WJ. Adsorption of cytotoxic anti-HLA antibodies with HLA class I immunosorbant beads. Transplantation 1990;49:925-31.
26. 2-M in patients under haemodialysis or after renal transplantation. Acta Clin Belg 1980;35 (Suppl 10):31-9.
27. 2-microglobulin in hemodialysed patients and normals. J Lab Clin Med 1991;118:153-65.
28. 2-microglobulin kinetics in end-stage renal failure. Kidney Int 1991;39:909-19.
29. 2-microglobulin turnover in dialyzed patients. Kidney Int 1992;42:1434-43.
30. Koch KM. Dialysis-related amyloidosis. Kidney Int 1992;41: 1416-29.
31. Chanard J, Vincent C, Caudwell V, Lavaud S, Toupance O, Wong T, Revillard JP. Beta 2-microglobulin metabolism in uremic patients who are undergoing dialysis. Kidney Int 1993;43:S83-7.
32. Keller C. LDL-apheresis: results of long-term treatment and vascular outcome. Atherosclerosis 1991;86:1-8.